Evotec: The Market Seems Split On The Company's Prospects, Buy

Evotec's 1H26 revenue fell nearly 20%, while adjusted EBITDA turned sharply negative, signaling significant deterioration in operating fundamentals. Confidence in management's targets has been withdrawn and valuation is being assessed on an as-is basis, with no credit for future guidance. Although liquidity remains strong and commercial momentum exists, profitability has not materialized and the turnaround timeline has been delayed.

Analysis

The investable issue is not the current earnings hole but a reset in the probability-weighted value of the platform: once management credibility is impaired, prospective partnership milestones and margin recovery deserve materially lower valuation multiples until independently visible in backlog conversion and cash generation. For a drug-discovery services business, negative operating leverage can persist longer than revenue weakness because scientific headcount and lab infrastructure are difficult to right-size without jeopardizing client programs; the next 1-3 quarters are therefore more likely to reveal restructuring costs than a clean earnings inflection.

EVO’s liquidity reduces near-term solvency risk but can perversely delay decisive cost action, making it a poor asymmetric short absent evidence of accelerating cash burn or capital raising. Relative beneficiaries are scaled CROs such as IQV and ICLR, which can absorb client outsourcing budgets with better utilization and less execution risk; CRL is the closer operating comp but retains its own bioprocessing and end-market risks. The contrarian case is that low expectations make even modest evidence of utilization recovery highly tradable, so the short thesis requires a catalyst rather than relying on depressed fundamentals alone.

The key falsifiers are sequential improvement in book-to-bill, laboratory utilization, operating cash flow, and a quantified cost-out plan that does not impair program delivery. A credible partner win is not sufficient by itself: investors should require disclosed economics, timing of revenue recognition, and evidence that incremental revenue converts to EBITDA. Over 6-18 months, sustained margin failure would force the market to value EVO primarily on net cash and asset recoverability rather than its discovery-platform narrative.

Key Decisions for Investors

• Maintain an underweight/avoid stance on EVO for the next 1-3 months; do not buy solely on balance-sheet support. Reassess only after two sequential reporting periods showing improving utilization and operating cash flow.
• For a bearish relative-value expression, consider long ICLR / short EVO in modest size over a 3-6 month horizon. The thesis is scale-driven outsourcing share gains and superior margin resilience; exit the short leg if EVO discloses a cost plan with measurable savings and positive EBITDA conversion guidance supported by backlog.
• Do not initiate an outright EVO short without monitoring net cash burn, covenant headroom, and financing needs. A deterioration in liquidity runway or a dilutive capital action would be the cleaner downside catalyst; absent that, borrow costs and takeover/speculation risk can dominate.
• Set an event-driven alert around the next results: a sequential revenue stabilization without EBITDA or cash-flow improvement is bearish and supports adding to the relative short; demonstrable positive operating leverage would invalidate the thesis and warrant covering.